Fresenius Medical Care AG (NYSE:FMS) Given Average Recommendation of “Hold” by Brokerages

Shares of Fresenius Medical Care AG (NYSE:FMS) have received an average rating of “Hold” from the seven ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $24.00.

FMS has been the subject of a number of recent analyst reports. Truist Financial upped their price target on shares of Fresenius Medical Care from $21.00 to $24.00 and gave the stock a “hold” rating in a report on Wednesday, May 15th. StockNews.com initiated coverage on Fresenius Medical Care in a report on Tuesday, June 25th. They issued a “strong-buy” rating on the stock.

Fresenius Medical Care Trading Down 0.4 %

Shares of NYSE:FMS opened at $19.09 on Friday. The business’s 50 day simple moving average is $20.83 and its 200 day simple moving average is $20.19. Fresenius Medical Care has a 1 year low of $16.37 and a 1 year high of $27.72. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.50 and a quick ratio of 1.14. The company has a market capitalization of $11.20 billion, a P/E ratio of 21.45, a P/E/G ratio of 1.02 and a beta of 0.93.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.10. The company had revenue of $5.13 billion for the quarter, compared to analysts’ expectations of $5.15 billion. Fresenius Medical Care had a return on equity of 5.29% and a net margin of 2.48%. On average, research analysts anticipate that Fresenius Medical Care will post 1.5 EPS for the current fiscal year.

Fresenius Medical Care Cuts Dividend

The business also recently declared an annual dividend, which was paid on Monday, June 3rd. Stockholders of record on Monday, May 20th were issued a dividend of $0.437 per share. The ex-dividend date was Friday, May 17th. This represents a dividend yield of 2.35%. Fresenius Medical Care’s dividend payout ratio (DPR) is presently 49.44%.

Institutional Trading of Fresenius Medical Care

A number of hedge funds have recently made changes to their positions in FMS. Pacer Advisors Inc. raised its holdings in Fresenius Medical Care by 14,252.1% in the 4th quarter. Pacer Advisors Inc. now owns 488,401 shares of the company’s stock valued at $10,173,000 after buying an additional 484,998 shares during the last quarter. Envestnet Asset Management Inc. increased its position in Fresenius Medical Care by 362.2% in the 3rd quarter. Envestnet Asset Management Inc. now owns 259,033 shares of the company’s stock valued at $5,580,000 after acquiring an additional 202,991 shares during the period. Moran Wealth Management LLC bought a new position in shares of Fresenius Medical Care during the fourth quarter valued at $3,247,000. Guardian Capital Advisors LP lifted its holdings in shares of Fresenius Medical Care by 16.7% during the fourth quarter. Guardian Capital Advisors LP now owns 123,715 shares of the company’s stock worth $2,556,000 after purchasing an additional 17,725 shares during the period. Finally, Partnership Wealth Management LLC bought a new stake in shares of Fresenius Medical Care in the fourth quarter worth $2,340,000. 8.25% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.